Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

LEASES (Tables)

LEASES (Tables)

6 Months Ended

Jun. 30, 2022

SCHEDULE OF FINANCING AND OPERATING LEASES

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

	Classification on the Balance Sheet	June 30, 2022
		(unaudited)
Assets
Financing lease assets	Property and equipment, net	$	620
Operating lease assets	Operating lease right of use assets		3,483
Total lease assets		$	4,103

Liabilities
Current
Financing lease liabilities	Other accrued expenses	$	68
Operating lease liabilities	Other accrued expenses		963
Total current lease liabilities		$	1,031
Noncurrent
Financing lease liabilities	Other long-term liabilities		24
Operating lease liabilities	Operating lease liabilities, net of current portion		2,691
Total long-term lease liabilities			2,715
Total lease liabilities		$	3,746

SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES

The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2022:

	Operating Leases		Financing Leases
2022	$	626	$	36
2023		897		60
2024		567		-
2025		402		-
2026-2030		1,924
Total minimum lease payments		4,416		96
Less: amount of lease payments representing effects of discounting		762		4
Present value of future minimum lease payments		3,654		92
Less: current obligations under leases		963		68
Long-term lease obligations	$	2,691	$	24

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES

As of June 30, 2022, contractual operating lease obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows:

			Less than		1 to 3		3 to 5		After
	Total		1 Year		Years		Years		5 Years
Operating lease obligations	$	4,416	$	626	$	1,464	$	816	$	1,510
Total	$	4,416	$	626	$	1,464	$	816	$	1,510